ImmunoGenesis doses 1st patient in phase 1/2 trial of IMGS-101 in combo with balstilimab & zalifrelimab to treat immune-excluded tumours: Houston Saturday, March 8, 2025, 18:00 Hr ...

Macbecin II was identified as a compound that upregulates MHC-I expression, enhancing immune-mediated cancer cell killing. In ...

In addition, immune T cells, typically in charge of fighting the tumor, were excluded from the tumor microenvironment, reducing the ability of the immune system to eliminate the tumor. Importantly ...

Methods: 111 patients undergoing curative-intent resection of colorectal liver metastases were stratified by age into those <50 years or >65 years old, and tumors were subjected to multiplex ...

Feb. 26, 2025 — New findings could help make immunotherapies for brain cancer more effective. The team analyzed almost 200,000 individual immune cells in tumor samples taken from patients with ...

Get Instant Summarized Text (Gist) A specific immune response involving CD4 + Th1 cells has been identified as potentially preventing the spread of breast cancer by targeting dormant cancer cells ...

Cancer is a disease primarily caused by genetic mutations in the body's cells, with certain mutations associated with particular types of cancer. While immune cells can recognize and eliminate ...

Cancer Immunol Res (2025) 13 (2_Supplement): B001.

However, subtyping of BC based on the tumor immune microenvironment (TIME) remains insufficiently explored, although such investigation may provide new insights into intratumor heterogeneity in BC and ...